Peptide-based strategies for overcoming multidrug-resistance in cancer therapy  

作　　者：Xiaofang Luo Ye Wu Xiaokun Zhang Min Tang Feiye Ju Zuodong Qin Gregory J Duns Wei-Dong Zhang Jiang-Jiang Qin Xin Luan 

机构地区：[1]Hunan Engineering Technology Research Center for Comprehensive Development and Utilization of Biomass Resources,College of Chemistry and Bioengineering,Hunan University of Science and Engineering,Yongzhou 425199,China [2]Shanghai Frontiers Science Center of TCM Chemical Biology,Institute of Interdisciplinary Integrative Medicine Research and Shuguang Hospital,Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China [3]Zhejiang Cancer Hospital,Hangzhou Institute of Medicine(HIM),Chinese Academy of Sciences,Hangzhou 310022,China [4]State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs,Institute of Medicinal Plant Development,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100700,China

出　　处：《Chinese Chemical Letters》2025年第1期110-118,共9页中国化学快报(英文版)

基　　金：supported by the Science and Technology Innovation Program of Hunan Province(No.2022RC1168);National Natural Science Foundation of China(Nos.82322073,82173846,82304533);CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2023-I2M-3-009);Key project at central government level:The ability establishment of sustainable use for valuable Chinese medicine resources(No.2060302);China Postdoctoral Science Foundation(No.2021M702215);Oriental Scholars of Shanghai Universities(No.TP2022081);Jiangxi Province Thousand Talents Program(No.jxsq2023102168);Young Talent Lifting Project of China Association of Chinese Medicine(No.CACM-(2021-QNRC2-A08));Shanghai Rising-Star Program(No.22QA1409100);Shanghai Sailing Program(No.22YF1445000);2021 Shanghai Science and Technology Innovation Action Plan(No.21S11902800);Three-year Action Plan for Shanghai TCM Development and Inheritance Program(Nos.ZY(2021-2023)-0208,ZY(2021-2023)-0401);High level Key Discipline of National Administration of Traditional Chinese Medicine(No.71);Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine(No.ZYYCXTD-D-202004);Innovation team of high-level local universities in Shanghai:Strategic Innovation Team of TCM Chemical Biology。

摘　　要：Despite ongoing advancements in cancer treatment,the emergence of primary and acquired resistance poses a significant challenge for both traditional chemotherapy and immune checkpoint blockade therapies.The demand for targeted therapeutics for multidrug-resistant cancer is more important than ever.Peptides,as emerging alternatives to current anticancer drugs,offer exquisite versatility in facilitating the design of novel oncology drugs,with the core superiorities of good biocompatibility and a low tendency to induce drug resistance.This review comprehensively introduces the pharmacological mechanisms of peptide-based drugs and strategies for overcoming multidrug resistance(MDR)in cancers,including inducing cell membrane lysis,targeting organelles,activating anticancer immune responses,enhancing drug uptake,targeting ATP-binding cassette(ABC)transporters,and targeting B-cell lymphoma-2(BCL-2)family proteins.Additionally,the current clinical applications of representative peptides in combating MDR cancers and their potential directions for medicinal chemistry research have been thoroughly discussed.This review offers essential insights into the novel treatment approaches for MDR cancers and highlights the trends and perspectives in this field.

关 键 词：Drug resistance Antitumor peptides Mechanism of action Targeted therapeutics IMMUNOTHERAPY Medicinal chemistry 

分 类 号：R730.5[医药卫生—肿瘤]